Skip to main content
. 2021 Feb 24;13(3):298. doi: 10.3390/pharmaceutics13030298

Figure 7.

Figure 7

Nuclease protection assay of mRNA: FSeNP nanocomplexes. Lane 1: Positive control (naked mRNA (0.3 µg)). Lane 2: Negative control (mRNA + 10% serum). Nanocomplexes at sub-optimum, optimum, and supra-optimum w/w binding ratios–(A) Lanes 3–5: CS-SeNP (1:4.5, 1:5 and 1:5.5) and Lanes 6–8: LA-CS- SeNP (1:5.5, 1:6 and 1:6.5); (B) Lanes 3–5: PEG-CS-SeNP (1:4.5; 1:5 and 1:5.5) and Lanes 6–8: PEG-LA-CS-SeNP (1:4.5; 1:5 and 1:5.5).